CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments
This article was originally published in The Tan Sheet
Executive Summary
OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.
You may also be interested in...
Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact
Proton pump inhibitor OTC switches since 2003 had a profound and sustained impact on outpatient health care visits – illustrating the potential for other switches to benefit US health care, a recent study suggests.
Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact
Proton pump inhibitor OTC switches since 2003 had a profound and sustained impact on outpatient health care visits – illustrating the potential for other switches to benefit US health care, a recent study suggests.
Dermatology OTC Switches Loom Next For Consumer Health Growth
Dermatology OTC switch products for acne, eczema and psoriasis are likely to emerge, says Kline analyst Laura Mahecha. Switches, the return of recalled OTC brands and market consolidation drove a 4.2% increase for the US consumer health market in 2015.